Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab versus zoledronic acid versus placebo for bone loss prevention in postmenopausal critically ill women
ACTRN12617000545369Phase 2Recruiting
- Sponsor
- University Hospital Geelong
- Start
- Apr 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoporosis comparing Denosumab, Zoledronic acid and Placebo (3 arms). Primary endpoint: Change in serum CTX. Started Apr 2018; status: recruiting.
02
Drugs
denosumabzoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ACTRN12617000545369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000545369.